It also targets SRC kinase and may be of benefit in PTCL with FYN mutations, where in vitro studies showed dose-dependent inhibition of the increased phosphorylation activity of FYN Leu174Arg, FYN Arg176Cys, and FYN Tyr531His mutant proteins by dasatinib [78]. This evidence concerns the gene FYN and mature T-cell and NK-cell non-Hodgkin lymphoma.